This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

NICE guidance - rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

NICE have suggested that (1):

  • rituximab, in combination with glucocorticoids, is recommended as an option for inducing remission in adults with anti-neutrophil cytoplasmic antibody [ANCA]-associated vasculitis (severely active granulomatosis with polyangiitis [Wegener's] and microscopic polyangiitis), only if:
    • further cyclophosphamide treatment would exceed the maximum cumulative cyclophosphamide dose or

    • cyclophosphamide is contraindicated or not tolerated or

    • the person has not completed their family and treatment with cyclophosphamide may materially affect their fertility or

    • the disease has remained active or progressed despite a course of cyclophosphamide lasting 3-6 months or

    • the person has had uroepithelial malignancy.

Notes (1):

  • rituximab is a genetically engineered chimeric (mouse/human) monoclonal antibody that depletes B cells by targeting cells bearing the CD20 surface marker

Reference:

Related pages

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.